Miltenyi Biomedicine

Miltenyi Biomedicine is a newly established biopharmaceutical company dedicated to developing innovative cell and gene therapies, providing cancer treatments and regenerative therapies for patients worldwide, as well as advancing regenerative therapies for Alzheimer's disease, Parkinson's disease, and diabetes. The company is currently developing several platforms, including chimeric antigen receptor T (CAR T) and CAR natural killer (CAR NK) cells, for the treatment of adult patients with hematologic malignancies.